Previous studies have shown that c-Met (Mesenchymal Epithelial Transition) antagonists are regarded as a kind of newer drugs in the treatment of non-small cell lung cancer (NSCLC). FDA-approved c-Met such as crizotinib and cabozantinib have been currently reported to present adverse effects when used in NSCLC therapy. This ranges from chest pain, unusual bleeding of the nose and mouth, fever and jaundice. In view of this, research is focus on identifying more potent compounds with no toxicity that can be used in NSCLC therapy.
The aim of this study is to explore from plant sources (musa acuminate) for the best-in-class drug-gable compound via computational tools.For this, twenty-eight (28) chemical compounds (phytochemicals) obtained from musa acuminate and retrieved from literatures were screened for their inhibitory effects on c-Met. Eugenol was the lead compound with a binding energy of -5.7.0kcal/mol. Molecular docking analysis was performed using PyRx, AutoDockVina option based on scoring functions and the target was validated so as to ensure that the right target was used for this analysis. These results explain why eugenol should be considered as one of the potential antagonist of c-Met in NSCLC treatment.
Impact Factor
2022: 6.012
This work is licensed under a